With investments exceeding 450 million Saudi Riyals, Eva Pharma is steadily progressing towards launching its advanced industrial complex for research and pharmaceutical manufacturing in Saudi Arabia, reported Zawya. Covering over 50,000 square meters, the complex will meet the needs of various therapeutic fields. It will specialize in manufacturing over 150 pharmaceutical products including cancer treatments, immunosuppressants, vaccines, and biologic drugs.
Moreover, a Memorandum of Understanding (MoU) signed with the Ministry of Investment emphasizes the importance of collaboration between the private and public sectors to elevate Saudi Arabia’s pharmaceutical industry.
Eva Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa, reinforces its commitment to the Saudi health sector. This includes laying the foundation for the industrial complex in Sudair City and opening an office in Riyadh. The MoU between Eva Pharma and the Ministry of Investment underlines their strategic partnership.
The industrial complex also aims to be a leading pharmaceutical manufacturing center in the region, offering innovative, sustainable, and accessible treatments. It will house a research and development center and five pharmaceutical factories. These include factories for cancer treatments and immunosuppressants. Other factories will produce biologic drugs, vaccines, tablets, inhalable powders, dual-layer tablets, and orally disintegrating pills. They will produce over 150 pharmaceutical products for various therapeutic needs in the Kingdom.
Eva Pharma‘s strategic expansion in Saudi Arabia underscores its commitment to meeting urgent patient needs. The industrial complex in Sudair City also aims to contribute to achieving Saudi Vision 2030’s targets. Moreover, it aligns with the Health Sector Transformation Program to increase private sector contribution to 50%, from the current 11%.